Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × liposomal doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 86 Breast Neoplasms 66 Fallopian Tube Neoplasms 36 Multiple Myeloma 26 Carcinoma, Ovarian Epithelial 24 Neoplasms 22 Triple Negative Breast Neoplasms 13 Lymphoma 13 Sarcoma 11 Neoplasm Metastasis 11 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 8 Lymphoma, Non-Hodgkin 7 Hodgkin Disease 7 Prostatic Neoplasms 6 Pancreatic Neoplasms 5 Neoplasms, Plasma Cell 5 Burkitt Lymphoma 5 Solid Tumors 4 Sarcoma, Kaposi 4 Sarcoma, Ewing 4 Lymphoma, T-Cell, Peripheral 4 Carcinoma 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Rhabdomyosarcoma 3 Osteosarcoma 3 Lymphoma, T-Cell 3 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡